The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient. Buy the report here.
Smarter leaders trust GlobalData
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
See Also:
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Platinum as an active pharmaceutical ingredient is a key innovation area in pharmaceutical
Platinum-based drugs are widely used for the treatment of cancer. Various emerging technologies such as dendrimers, polymers, liposomes, nanotubes, nano-formulations, and combination studies show promise for the safe delivery of platinum-based compounds and help to eliminate unwanted side-effects. Apart from cancer, various platinum-based compounds are being investigated for diseases, primarily in CNS, immunology, respiratory and ENT disorders.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 240 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of platinum as active pharmaceutical ingredient.
Key players in platinum as active pharmaceutical ingredient – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local.’
Patent volumes related to platinum as active pharmaceutical ingredient
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| Vertex Pharmaceuticals | 223 | Unlock Company Profile |
| F. Hoffmann-La Roche | 213 | Unlock Company Profile |
| Bristol-Myers Squibb | 210 | Unlock Company Profile |
| Otsuka Holdings | 208 | Unlock Company Profile |
| E. Merck | 151 | Unlock Company Profile |
| Amgen | 120 | Unlock Company Profile |
| Pharma Mar | 119 | Unlock Company Profile |
| Pierre Fabre Foundation | 92 | Unlock Company Profile |
| Eagle Pharmaceuticals | 71 | Unlock Company Profile |
| Regeneron Pharmaceuticals | 67 | Unlock Company Profile |
| Ipsen | 66 | Unlock Company Profile |
| Johnson & Johnson | 65 | Unlock Company Profile |
| Esteve Pharmaceuticals | 62 | Unlock Company Profile |
| Arcus Biosciences | 61 | Unlock Company Profile |
| C. H. Boehringer Sohn | 61 | Unlock Company Profile |
| Pfizer | 59 | Unlock Company Profile |
| Eli Lilly and | 59 | Unlock Company Profile |
| AbbVie | 59 | Unlock Company Profile |
| Spectrum Pharmaceuticals | 58 | Unlock Company Profile |
| Novartis | 58 | Unlock Company Profile |
| Mayo Clinic | 56 | Unlock Company Profile |
| GSK | 53 | Unlock Company Profile |
| Bayer | 52 | Unlock Company Profile |
| Astellas Pharma | 46 | Unlock Company Profile |
| Takeda Pharmaceutical | 46 | Unlock Company Profile |
| Sprint Bioscience | 45 | Unlock Company Profile |
| Merck & Co | 42 | Unlock Company Profile |
| Superlab Far East | 41 | Unlock Company Profile |
| United Nations Industrial Development Organization | 41 | Unlock Company Profile |
| Ono Pharmaceutical | 39 | Unlock Company Profile |
| Polaris Pharmaceutical Group | 39 | Unlock Company Profile |
| Komipharm International | 35 | Unlock Company Profile |
| Saniona | 32 | Unlock Company Profile |
| Gilead Sciences | 32 | Unlock Company Profile |
| Cavion | 32 | Unlock Company Profile |
| Aslan Pharmaceuticals | 31 | Unlock Company Profile |
| Hanmi Science | 30 | Unlock Company Profile |
| Corcept Therapeutics | 30 | Unlock Company Profile |
| MEI Pharma | 30 | Unlock Company Profile |
| Zymeworks | 30 | Unlock Company Profile |
| Bio-Bedst | 30 | Unlock Company Profile |
| Mayne Pharma Group | 30 | Unlock Company Profile |
| Merrimack Pharmaceuticals | 30 | Unlock Company Profile |
| Intensity Therapeutics | 29 | Unlock Company Profile |
| Eisai | 29 | Unlock Company Profile |
| Enzychem Lifesciences | 28 | Unlock Company Profile |
| Help/Systems | 28 | Unlock Company Profile |
| RDInnovation | 28 | Unlock Company Profile |
| Helperby Therapeutics | 26 | Unlock Company Profile |
| Alfasigma | 26 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Vertex Pharmaceuticals is one of the leading patent filers in platinum-based drug therapies. The company has filed several patents involving platinum compounds that target ATR tyrosine kinase and is involved in developing drugs for the treatment of pancreatic cancer and non-small cell lung cancer.
In terms of application diversity, Oncolytics Biotech is the top company, followed by PharmAust and Calgent Biotechnology. By means of geographic reach, Komipharm International holds the top position. Whilst Amgen and Novartis are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
